Equity Field Notes from temporal sources

[DanWebzster]

SPHS has a Prostate Cancer drug that had positive Ph2B results after a single dose.

Despite this, the stock sank 40% because one out of 35 patients died. The death is being investigated. The investigation will last at least until August/18.

29% of the patients who topsalyn had not detectable cancer after a single dose. 17% had complete responses.

450 patients have been administered Topsalyn over the course of its clinical history. One patient died. The one that died had a second dose.

Cash runway is into Q2/19, but they will likely raise cash in 2018.